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        INTRODUCTION  
  Cortisol secretion from the adrenal zona fasciculata 
(AZF) occurs under the control of the pituitary peptide 
ACTH (adrenocorticotropic hormone) (  Simpson and 
Waterman, 1988  ). The molecular mechanisms that cou-
ple ACTH receptor activation to cortisol production are 
only partially understood. Early studies established that 
cAMP was the principal intracellular messenger for 
ACTH in AZF cells (  Haynes and Berthet, 1957  ;   Grahame-
Smith et al., 1967  ;   Richardson and Schulster, 1973  ;   Sala 
et al., 1979  ). ACTH stimulates cAMP synthesis in AZF 
cells, while cAMP mimics the steroidogenic actions of 
ACTH (Haynes et al., 1959;   Roesler et al., 1988  ;   Simpson 
and Waterman, 1988  ;   Waterman, 1994  ). Accordingly, 
bovine AZF cells express a high affi  nity, MC2-R melano-
cortin receptor coupled to adenylate cyclase through G  s   
(  Penhoat et al., 1989  ;   Raikhinstein et al., 1994  ). 
  Although cAMP appears to function as the primary 
intracellular messenger, Ca 
2+   may also act pivotally in 
ACTH-stimulated corticosteroid secretion. At concen-
trations that produce little or no measurable increase in 
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cAMP synthesis, ACTH has been reported to increase 
intracellular Ca 
2+   concentration and stimulate cortisol 
secretion in bovine AZF cells (  Yanagibashi et al., 1990  ; 
  Kimoto et al., 1996  ). Similarly, the   O  -nitrophenyl, sulfe-
nyl derivative of ACTH (NPS-ACTH) stimulates large 
increases in [Ca 
2+  ]  i   and corticosteroid secretion at con-
centrations that trigger no measurable increases in cAMP 
synthesis in either rat or bovine AZF cells (  Moyle et al., 
1973  ;   Yamazaki et al., 1998  ). Overall, these results sug-
gest that cAMP and Ca 
2+   are dual messengers that are 
both required to mediate the full steroidogenic response 
to ACTH. 
  In this regard, a role for electrical events and depolar-
ization-dependent Ca 
2+   entry in ACTH-stimulated corti-
sol secretion has been established (  Enyeart et al., 1993  ; 
  Mlinar et al., 1993  ). Specifi  cally, bovine AZF cells ex-
press bTREK-1 leak-type K 
+   channels, which set the rest-
ing membrane potential (  Mlinar et al., 1993  ;   Enyeart 
et al., 2002  ). ACTH receptor activation is coupled to mem-
brane depolarization and Ca 
2+   entry through the in-
hibition of bTREK-1 channels ( Enyeart et al., 1993, 1996 ; 
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activated by cAMP. The selective Epac activator, 8-pCPT-2  ’  -O-Me-cAMP, applied intracellularly through the patch 
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TREK-1 inhibition, ACTH, NPS-ACTH, forskolin, and 8-pCPT-2  ’  -O-Me-cAMP also inhibit these K 
+   channels by a 
PKA-independent signaling pathway. The convergent inhibition of bTREK-1 through parallel PKA- and Epac-de-
pendent mechanisms may provide for failsafe membrane depolarization by ACTH. 
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and cAMP inhibit bTREK-1 in bovine AZF cells. The 
goal of this study was to determine whether ACTH and 
cAMP could inhibit bTREK-1 by Epac2 as well as PKA-
dependent pathways. 
  Some of these results have been reported in abstract 
form (H. Liu, J.A. Enyeart, and J.J. Enyeart. 2008.   Biophys  .   J  . 
94:2181). 
  MATERIALS AND METHODS  
  Materials 
  Tissue culture media, antibiotics, fi  bronectin, and FBS were ob-
tained from Invitrogen. Coverslips were from Bellco. PBS, en-
zymes, 1,2   bis  -(2-aminophenoxy)ethane-  N,N,N  ’  ,N  ’    ’    -tetraacetic acid 
(BAPTA), MgATP, collagenase, DNase, H-89, nystatin, 8-pCPT-
cAMP, and ACTH (1  –  24), AMP-PNP, and Rp-cAMPS were obtained 
from Sigma-Aldrich. PKI(6  –  22) amide and PKI(14  –  22)myristolated 
were purchased from EMD Biosciences, Inc. 8-pCPT-2  ’  -O-Me-
cAMP (Biolog #C041) was purchased from Axxora, LLC. Human 
full-length cDNA for Epac2 (cAMP-GEFII, clone ID# 4823935) 
was purchased from Open Biosystems. p3-CD8 clone was provided 
by B. Seed (Massachusetts General Hospital, Boston, MA). Signa-
Tect cAMP-dependent protein kinase (PKA) assay system was 
from Promega. [     
32  P] ATP was purchased from Perkin Elmer. 
NPS-ACTH was custom synthesized by Celtek Peptides. 
  Isolation and Culture of AZF Cells 
  Bovine adrenal glands were obtained from steers (age 2  –  3 yr) at a 
local slaughterhouse. Isolated AZF cells were obtained and pre-
pared as previously described (  Enyeart et al., 1997  ). After isola-
tion, cells were either resuspended in DMEM/F12 (1:1) with 10% 
FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and the anti-
oxidants     -tocopherol (1   μ  M), 20 nM selenite, and 100   μ  M ascorbic 
acid (DMEM/F12+) and plated for immediate use, or resuspended 
in FBS/5% DMSO, divided into 1 ml aliquots, and stored in liquid 
nitrogen for future use. To ensure cell attachment, dishes were 
treated with fi  bronectin (10   μ  g/ml) at 37  °  C for 30 min and then 
rinsed with warm, sterile PBS immediately before adding cells. 
For patch clamp experiments, cells were plated in DMEM/F12+ 
in 35-mm dishes containing 9-mm 
2   glass coverslips. Coverslips 
were treated with fi  bronectin (10   μ  g/ml) as described above. 
Cells were maintained at 37  °  C in a humidifi  ed atmosphere of 
95% air  –  5% CO  2  . 
  Measurement of Epac2 mRNA 
  RNeasy columns (QIAGEN) that had been treated with RNase-
free DNase (QIAGEN) to remove genomic contamination were 
used to extract total RNA from AZF cells that had been cultured 
for 48 h both with and without ACTH (2 nM) or confl  uent HEK293 
cells. Poly(A) 
+   mRNA was extracted from total RNA using a Poly(A) 
Pure kit (Ambion). 7   μ  g of total or poly(A) 
+   mRNA were separated 
on a denaturing 8% formaldehyde, 1.0% agarose gel, and trans-
ferred to a nylon membrane (Gene Screen Plus, NEN). The RNA 
was fi  xed to the membrane by UV cross-linking using a Stratalinker 
(Stratagene). Northern blots were prehybridized in heat-sealable 
plastic bags for 2 h at 42  °  C in ULTRAhyb (Ambion) and then 
hybridized with a [      
32  P]dCTP-labeled 700-bp   XHO1   fragment of 
h-Epac2 DNA overnight at 42  °  C in minimal volume of ULTRAhyb. 
After 18  –  24 h, membrane was washed twice at room temperature 
in 2  ×   SSPE for 15 min, twice at 40  °  C in 1  ×   SSPE, 1% SDS for 
30 min, with a fi  nal wash at 40  °  C with 0.1  ×   SSPE, 1% SDS for 15 min 
before exposing to a storage phosphor screen for 4  –  12 h. North-
ern autoradiogram was imaged using a Typhoon 9200 variable 
mode phosphorimager. 
  Mlinar et al., 1993  ). Accordingly, organic Ca 
2+   antago-
nists inhibit T-type Ca 
2+   channels at concentrations that 
also inhibit ACTH-stimulated cortisol secretion (  Enyeart 
et al., 1993  ). The NPS-ACTH  –  stimulated increase in 
[Ca 
2+  ]  i   in bovine AZF cells is also inhibited by organic 
Ca 
2+   antagonists at concentrations that inhibit T-type Ca 
2+   
channels (  Yamazaki et al., 1998  ). Thus, bTREK-1 appears 
to link ACTH receptor activation to cortisol secretion 
through depolarization-dependent Ca 
2+   entry. 
  The signaling mechanisms by which ACTH inhibits 
bTREK-1 channels are incompletely understood. They 
may involve multiple cAMP- and Ca 
2+  -dependent pathways. 
Specifi  cally, neuronal TREK-1 channels are inhibited by 
cAMP through PKA-dependent phosphorylation of a 
carboxyl-terminal serine that is also present in bTREK-1 
channels (  Patel et al., 1998  ;   Honor  é  , 2007  ). Although 
native bTREK-1 channels can also be inhibited by this 
mechanism, ACTH and cAMP inhibit bTREK-1 chan-
nels in AZF cells in the presence of any of several PKA 
antagonists (  Enyeart et al., 1996  ). 
  While all of the cAMP-dependent actions of ACTH in 
AZF cells were previously thought to be mediated by 
PKA, alternative signaling pathways for cAMP-mediated 
responses are likely present in these cells. Specifi  cally, 
two cAMP-activated guanine nucleotide exchange factors, 
Epac1 and Epac2 (also known as cAMP-GEFI and cAMP-
GEFII), have been identifi  ed and implicated in the reg-
ulation of proteins including ion channels (  de Rooij et al., 
1998  ;   Kawasaki et al., 1998  ;   Holz et al., 2008  ). While 
Epac1 is expressed in many tissues, Epac2 is robustly ex-
pressed in selected areas of the brain and the adrenal 
glands of rats and humans (  Kawasaki et al., 1998  ). This 
raises the possibility that cAMP-dependent inhibition of 
bTREK-1 in the adrenal gland is mediated through sep-
arate PKA- and Epac2-dependent mechanisms. 
  In addition, studies with NPS-ACTH raise the possibil-
ity that ACTH might inhibit bTREK-1 by a Ca 
2+  -depen-
dent mechanism that is independent of both cAMP 
and PKA. In this regard, angiotensin II (AngII) which 
also stimulates cortisol secretion from bovine AZF cells, 
inhibits bTREK-1 in these cells by separate Ca 
2+  - and 
ATP-dependent pathways (  Gomora and Enyeart, 1998  ; 
  Enyeart et al., 2005  ;   Liu et al., 2007  ). Overall, our results 
and those of other investigators suggest that ACTH may 
regulate bTREK-1 channels by multiple cAMP- and Ca 
2+  -
dependent pathways. 
  In this regard, Epac1 and Epac2 possess cAMP bind-
ing domains that lack a specifi  c glutamate residue pres-
ent in the binding domain of PKA (Enserink et al., 
2002). Using this information and rational drug design, 
novel cAMP analogues were developed that, at appro-
priate concentrations, selectively activate the Epac pro-
teins (Enserink et al., 2002; Christensen et al., 2003). 
We have used one of these, 8-pCPT-2  ’  -O-Me-cAMP, along 
with other agents involved in cAMP metabolism to fur-
ther characterize the signaling pathways by which ACTH     Liu et al.  281
  Transient Transfection and Visual Identiﬁ  cation of HEK293 
Cells Expressing bTREK-1 
  For patch clamp recording of bTREK-1 currents, HEK293 cells 
were cotransfected with a mixture of pCR 
  ®   3.1-Uni-bTrek-1 and an 
expression plasmid (p3-CD8) for the      subunit of the human 
CD8 lymphocyte surface antigen at a 5:1 ratio using Lipofectamine 
(Life Technologies). Cells were visualized 1  –  2 d post transfection 
after a 15-min incubation with anti-CD8 antibody-coated beads 
(Dynal Biotech Inc.) as previously described (  Jurman et al., 1994  ). 
  RESULTS  
  Bovine AZF cells express two types of K 
+   channels: a volt-
age-gated, rapidly inactivating Kv1.4 channel, and a two 
pore domain, four transmembrane-spanning segment 
(2P/4TMS) bTREK-1 background K 
+   channel (  Mlinar 
and Enyeart, 1993  ;   Mlinar et al., 1993  ;   Enyeart et al., 2000  ; 
  Enyeart et al., 2002  ). In whole cell patch clamp record-
ings, bTREK-1 amplitude typically increases with time to 
a steady-state maximum. The absence of time- and voltage-
dependent inactivation allows bTREK-1 K 
+   currents to 
be isolated in whole cell recordings using either of two 
voltage clamp protocols. When voltage steps of several 
hundred milliseconds duration are applied from a hold-
ing potential of     80 mV, bTREK-1 K 
+   current can be 
measured near the end of a voltage step when the Kv1.4 
K 
+   current has fully inactivated (  Fig. 1, A  –  C  , left traces).   
Alternatively, bTREK-1 current can be selectively acti-
vated by an identical voltage step applied immediately 
after a 10-s prepulse to     20 mV has fully inactivated Kv1.4 
channels (  Fig. 1, A  –  C  , right traces). 
  In whole cell recordings from bovine AZF cells, we 
previously showed that ACTH inhibits bTREK-1 current 
by a mechanism that was insensitive to PKA antagonists 
H-89 and a synthetic inhibitory peptide PKI(5  –  24) when 
either was added to the recording pipette (  Enyeart 
et al., 1996  ). This result indicated that ACTH could in-
hibit bTREK-1 by a PKA-independent pathway. In the 
present study, we measured the inhibition of bTREK-1 
with the addition of a second PKI inhibitory peptide, 
PKI(6  –  22) amide, to the pipette solution, either alone 
or in combination with H-89. PKI(6  –  22) amide is a syn-
thetic peptide patterned after a portion of the naturally 
occurring PKA inhibitory peptide and inhibits PKA with 
a reported IC  50   of 1.7 nM (  Glass et al., 1989  ). When added 
to cytoplasmic extracts from AZF cells, PKI(6  –  22) am-
ide (4   μ  M) and H-89 (10   μ  M) completely inhibited PKA 
activated by maximally effective concentrations of cAMP 
(see   Fig. 7 C  ). 
  In contrast, when applied directly to the cytoplasm of 
AZF cells through the patch electrode, these PKA inhib-
itors failed to alter the potency or effectiveness of ACTH 
as an inhibitor of bTREK-1. ACTH inhibits bTREK-1 with 
an IC  50   of 4.1 pM (  Mlinar et al., 1993  ). With standard 
pipette solution, ACTH (200 pM) inhibited bTREK-1 
almost completely (95.2   ±   2.4%,   n   = 4) (  Fig. 1, A and D  ). 
The addition of PKI(6  –  22) amide (2 or 4   μ  M) to the 
  Patch Clamp Experiments 
  Patch clamp recordings of K 
+   channel currents were made in the 
whole cell and perforated patch confi  gurations from bovine AZF 
cells. The standard external solution consisted of 140 mM NaCl, 
5 mM KCl, 2 mM CaCl  2  , 2 mM MgCl  2  , 10 mM HEPES, and 5 mM 
glucose, with pH adjusted to 7.3 using NaOH. The standard pi-
pette solution consisted of 120 mM KCl, 1 mM CaCl  2  , 2 mM 
MgCl  2  , 11 mM BAPTA, 10 mM HEPES, 5 mM ATP, and 200   μ  M 
GTP, with pH titrated to 6.8 using KOH. The buffering capacity of 
pipette solutions was varied by adding combinations of CaCl  2   and 
BAPTA or EGTA using the Bound and Determined software pro-
gram (  Brooks and Storey, 1992  ). Low and high capacity Ca 
2+   buff-
ering solutions contained 0.5 mM EGTA and 11 mM BAPTA, 
respectively. The low capacity Ca 
2+   buffering solution was nomi-
nally Ca 
2+   free. [Ca 
2+  ]  i   was buffered to 22 nM in the high capacity 
buffering solution. The patch pipette solution was maintained at 
pH 6.8 to enhance the expression of bTREK-1. For perforated 
patch recordings, the pipette solution contained 130 mM KCl, 
2 mM MgCl  2  , and 20 mM HEPES, with pH adjusted to 6.8 using 
KOH. The pipette tip was fi  lled with this solution and backfi  lled 
with this same solution supplemented with 120   μ  g/ml nystatin. 
Nystatin stock solutions (30 mg/ml) were made fresh daily in 
DMSO. Perforated patch recordings were made as previously de-
scribed (  Horn and Marty, 1988  ). 
  Recording Conditions and Electronics 
  AZF cells were used for patch clamp experiments 2  –  12 h after 
plating. Typically, cells with diameters   <  15   μ  m and capacitances of 
10  –  15 pF were selected. Coverslips were transferred from 35-mm 
culture dishes to the recording chamber (volume: 1.5 ml) that 
was continuously perfused by gravity at a rate of 3  –  5 ml/min. For 
whole cell recordings, patch electrodes with resistances of 1.0  – 
2.0 M  Ω   were fabricated from Corning 0010 glass (World Precision 
Instruments). These electrodes routinely yielded access resis-
tances of 1.5  –  4.0 M  Ω   and voltage-clamp time constants of   <  100   μ  s. 
K 
+   currents were recorded at room temperature (22 –  25  °  C) accord-
ing to the procedure of Hamill et al. (  1981  ) using a List EPC-7 
patch clamp amplifi  er. 
  Pulse generation and data acquisition were done using a per-
sonal computer and PCLAMP software with Digidata 1200 interface 
(Axon Instruments, Inc.). Currents were digitized at 2  –  10 kHz after 
fi  ltering with an 8-pole Bessel fi  lter (Frequency Devices). Linear 
leak and capacity currents were subtracted from current records 
using summed scaled hyperpolarizing steps of 1/2 to 1/4 pulse 
amplitude. Data were analyzed using CLAMPFIT 9.2 (Molecular 
Devices) and SigmaPlot (version 10.0) software. Drugs were applied 
by bath perfusion, controlled manually by a six-way rotary valve. 
  PKA Assay 
  PKA activity was measured with a SignaTECT cAMP-dependent 
protein kinase assay kit (Promega). This kit uses PKA-dependent 
phosphorylation of biotinylated peptides as a measure of PKA ac-
tivity. AZF cells were plated on 60-mm fi  bronectin-treated dishes 
in DMEM/F12+ at a density of     4   ×   10 
6   cells/dish. After 24 h, the 
serum-supplemented media was removed and replaced with ei-
ther control media (DMEM/F12+) or the same media containing 
myristolyated PKI(14  –  22) and H-89. At the end of the incubation 
period, cells were washed two times with ice-cold PBS and sus-
pended in 500   μ  l of cold extraction buffer (25 mM Tris-HCl pH 
7.4, 0.5 mM EGTA, 10 mM     -mercaptoethanol, 0.5 mM Pefabloc-
SC [Roche Applied Science], and protease inhibitors with EDTA 
[Complete Mini protease inhibitor cocktail tablet, 1 per 10 ml ly-
sis solution, Roche Applied Science]). Lysates were homogenized 
using a cold Dounce homogenizer then centrifuged for 5 min at 
4  °  C at 14,000   g  . 5-  μ  l samples of lysate supernatant were assayed 
using the SignaTECT cAMP-dependent protein kinase assay sys-
tem. Each experimental condition was assayed in quadruplicate. 282   ACTH Inhibits bTREK-1 through Multiple cAMP-dependent Pathways  
nel open probability was markedly reduced only at neg-
ative potentials. 
  To determine whether ACTH or cAMP converted na-
tive bTREK-1 channels into voltage-gated channels, we 
measured bTREK-1 inhibition by ACTH (200 pM) or 
the membrane-permeable cAMP analogue 8-pCPT-cAMP 
over a wide range of test potentials. When bTREK-1 was 
activated by voltage steps between    60 and +40 mV, ACTH 
selectively inhibited this current almost completely at 
every test potential ( Fig. 2 A ).   Similarly, when bTREK-1 cur-
rents were measured in response to voltage ramps between 
    100 and +100 mV, ACTH totally inhibited this current, 
even at the most positive test potential (  Fig. 2 A  ). 
  In similar experiments, the membrane-permeable cAMP 
analogue 8-pCPT-cAMP (300   μ  M) inhibited bTREK-1 
with equal effectiveness over the same range of test volt-
ages (  Fig. 2 B  ). These results indicate that neither ACTH 
nor cAMP inhibit bTREK-1 solely by converting it to a 
voltage-gated channel through PKA phosphorylation. 
  pipette solution did not blunt ACTH-induced inhibition 
of bTREK-1 (  Fig. 1 D  ). PKI(6  –  22) amide in combina-
tion with H-89 (5 or 10   μ  M) also failed to signifi  cantly 
reduce ACTH-mediated inhibition of bTREK-1 (  Fig. 1, 
B and D  ). The PKA inhibitors were also ineffective at 
reducing bTREK-1 inhibition by ACTH at a concentra-
tion of 20 pM where   <  2% of all receptors would be acti-
vated (  Buckley and Ramachandran, 1981  ;   Raikhinstein 
et al., 1994  ) (  Fig. 1, C and D  ). 
  bTREK-1 Inhibition by ACTH and cAMP Is 
Voltage Independent 
  These results provide further proof that ACTH inhibits 
bTREK-1 by a PKA-independent mechanism. In this re-
gard, cAMP acting through PKA was reported to inhibit 
hippocampal TREK-1 channels by a mechanism that 
converted TREK-1 from a voltage-insensitive leak chan-
nel into a voltage-gated outward rectifi  er (  Bockenhauer 
et al., 2001  ). When phosphorylated by PKA, TREK-1 chan-
  Figure 1.     Effect of PKA inhibitors on bTREK-1 
inhibition by ACTH. Whole cell K 
+   currents 
were recorded from AZF cells in response to 
voltage steps applied from     80 mV at 30-s in-
tervals with or without depolarizing prepulses 
to     20 mV. Pipettes contained standard so-
lution or the same solution supplemented 
with PKI(6  –  22) amide (2 or 4   μ  M) alone or 
in combination with H-89 (5 or 10   μ  M). Af-
ter bTREK-1 reached a stable maximum, cells 
were superfused with ACTH (1 –  24) (200 pM). 
(A  –  C) K 
+   current traces recorded with (right 
traces) and without (left traces) depolarizing 
prepulses, and corresponding plot of bTREK-1 
amplitudes with (open circles) and without 
(closed circles) depolarizing pulses. Num-
bers on traces correspond to those on plots. 
(D) Summary of experiments as in A  –  C. Bars 
indicate mean   ±   SEM of bTREK-1 inhibition 
by 20 or 200 pM ACTH with or without PKA 
inhibitors as indicated.         Liu et al.  283
et al., 2007  ). The standard pipette solution containing 
5 mM MgATP with Ca 
2+   strongly buffered by 11 mM BAPTA 
facilitates selective activation of an ATP hydro  lysis-de-
pendent pathway. The Ca 
2+  -dependent pathway can be 
selectively activated with a pipette solution containing 
UTP instead of ATP, and 0.5 mM EGTA instead of 11 mM 
BAPTA (  Enyeart et al., 2005  ). 
  It was discovered that NPS-ACTH inhibited bTREK-1 
only through an ATP hydrolysis  –  dependent pathway. 
With pipette solution designed to permit selective acti-
vation of a Ca 
2+  -dependent pathway, NPS-ACTH (1 nM) 
failed to signifi  cantly inhibit bTREK-1. In contrast, AngII 
(10 nM) in these same experiments inhibited bTREK-1 by 
72.1   ±   4.2% (  n   = 3) (  Fig. 3 A  ).   With pipette solution that 
allowed selective activation of the ATP-dependent pathway, 
NPS-ACTH reversibly and completely inhibited bTREK-1 
with an IC  50   of 20.0 pM (  Fig. 3, B and C  ). 
  These results suggested that NPS-ACTH may inhibit 
bTREK-1 by the same pathways as ACTH, although less 
Overall, these fi  ndings are consistent with the hypothesis 
that ACTH inhibits bTREK-1 through separate PKA-
dependent and -independent mechanisms. 
  NPS-ACTH Inhibits bTREK-1 by a PKA- and Ca 
2+  -
independent Mechanism 
  Although our results are consistent with a model wherein 
ACTH inhibits bTREK-1 through parallel cAMP-de-
pendent paths, they do not exclude the possibility that 
inhibition could also occur through a separate Ca 
2+  -de-
pendent mechanism. 
  NPS-ACTH reportedly increases [Ca 
2+  ]  i   in bovine AZF 
cells with little or no increase in cAMP synthesis ( Yamazaki 
et al., 1998 ). This peptide was used to determine if ACTH 
could inhibit bTREK-1 by a Ca 
2+  -dependent pathway that 
is independent of cAMP. In this regard, AngII inhibits 
bTREK-1 by parallel Ca 
2+  - and ATP hydrolysis  –  dependent 
signaling pathways that can be activated separately using 
two different pipette solutions (  Enyeart et al., 2005  ;   Liu 
  Figure 2.     bTREK-1 inhibition by ACTH and 
8-pCPT-cAMP is voltage independent. bTREK-1 
was permitted to grow to a stable maximum be-
fore whole cell K 
+   currents were activated in re-
sponse to voltage steps or voltage ramps before 
and after superfusion of ACTH or 8-pCPT-cAMP. 
Voltage steps were applied at 30-s intervals in 10-mV 
increments from a holding potential of     80 mV 
to test potentials from     60 to +40 mV. Voltage 
ramps were applied at 100 mV/s to potentials 
between +100 and     100 mV from a holding po-
tential of 0 mV. (A) Effect of ACTH: K 
+   currents 
were recorded in response to voltage steps or volt-
age ramps before and after steady-state block by 
ACTH (200 pM). Top: current traces in response 
to voltage steps before and after ACTH. Bottom 
left: bTREK-1 amplitudes plotted against test 
potential before (closed circles) and after (open 
circles) ACTH. Bottom right: bTREK-1 current 
traces in response to ramp voltages before and 
after ACTH. (B, left) bTREK-1 amplitudes plot-
ted against test potential in control saline (closed 
circles) and after 8-pCPT-cAMP (open circles). 
(B, right) bTREK-1 current traces in response to 
ramp voltages before and after 8-pCPT-cAMP.     284   ACTH Inhibits bTREK-1 through Multiple cAMP-dependent Pathways  
ACTH could be indicative of a cAMP-independent, 
rather than a PKA-independent, action of cAMP. The 
di-terpene forskolin directly activates adenylate cyclase, 
increasing intracellular cAMP (  Awad et al., 1983  ). If 
cAMP inhibits bTREK-1 in AZF cells solely through 
  activation of PKA, then including PKA inhibitors in the 
recording pipette should block bTREK-1 inhibition by 
forskolin. Under control conditions, forskolin (2.5   μ  M) 
inhibited bTREK-1 current by 76.9   ±   9.3% (  n   = 4) (  Fig. 
4 A  ).   The addition of PKI(6  –  22) amide and H-89 to 
the pipette solution, at concentrations that completely 
inhibited PKA, failed to signifi  cantly reduce bTREK-1 
inhibition by forskolin (  Fig. 4, B and C  ). These fi  nd-
ings are consistent with the hypothesis that ACTH 
and cAMP inhibit bTREK-1 by the same PKA-indepen-
dent mechanism. 
  Effect of 8-pCPT-2  ’  -O-Me-cAMP on PKA Activity and 
bTREK-1 Current in Perforated Patch Recordings 
  8-pCPT-2  ’  -O-Me-cAMP has been reported to be a rela-
tively selective activator of Epac proteins. It binds to 
Epac1 with 100-fold higher affi  nity than the cyclic nu-
cleotide binding domain of the PKA regulatory subunit 
(Enserink et al., 2002; Christensen et al., 2003). When 
applied to cells in culture at concentrations up to 100   μ  M, 
potently. In this regard, the activation of PKA by ACTH 
in AZF cells serves as a remarkably sensitive measure 
of cAMP synthesis. In bovine AZF cells, ACTH activates 
PKA with an EC  50   of 1.4 pM (  Enyeart and Enyeart, 1998  ). 
We found that NPS-ACTH activated PKA in AZF cells, 
but much less potently, with an EC  50   of 336 pM (  Fig. 3 C  ). 
Although less potent than ACTH, NPS-ACTH was equally 
effective as a PKA activator at maximum concentrations 
(unpublished data). 
  These results show that NPS-ACTH increases cAMP 
synthesis in AZF cells to a level suffi  cient to activate PKA. 
However, they also indicate that bTREK-1 inhibition by 
NPS-ACTH occurs at concentrations that produce minimal 
activation of PKA. Accordingly, we found that bTREK-1 
inhibition by NPS-ACTH was not affected by including 
PKA inhibitors in the patch pipette (  Fig. 3 D  ). Overall, 
these experiments showed that NPS-ACTH increases 
cAMP synthesis in AZF cells, but can inhibit bTREK-1 by 
a PKA- and Ca 
2+  -independent mechanism. 
  Forskolin Inhibits bTREK-1 by a PKA-
independent Mechanism 
  Although all of the actions of ACTH in the adrenal 
cortex may require the synthesis of cAMP, the failure 
of PKA inhibitors to suppress bTREK-1 inhibition by 
  Figure 3.     Inhibition of 
bTREK-1 by NPS-ACTH is 
Ca 
2+   and PKA independent. 
The inhibition of bTREK-1 
in bovine AZF cells by NPS-
ACTH was measured in whole 
cell patch clamp recordings us-
ing pipette solutions that per-
mitted or blocked activation of 
Ca 
2+  , ATP, or PKA-dependent 
signaling. K 
+   currents were re-
corded at 30-s intervals in re-
sponse to voltage steps to 
+20 mV from a holding poten-
tial of     80 mV. After currents 
reached a stable maximum, 
cells were superfused with 
NPS-ACTH. (A and B) Effect 
of NPS-ACTH on bTREK-1 
through Ca 
2+  - and ATP hydro-
lysis  –  dependent pathways. 
bTREK-1 current amplitudes 
with (open circles) and without 
(closed circles) depolarizing 
prepulses are plotted against 
time. Pipette solutions con-
tained (A) 2 mM UTP, 0.5 mM 
EGTA, (B) 5 mM MgATP, 
11 mM BAPTA. NPS-ACTH and AngII were superfused at indicated times. (C) Concentration dependence of bTREK-1 inhibition and 
PKA activation by NPS-ACTH were measured in AZF cells and cell, respectively. Data were fi  t with an equation of the form (dotted line) 
I/I  MAX   = 1/[1 + (X/IC  50  ) 
B  ], where X is the NPS-ACTH concentration, and B is the Hill coeffi  cient. IC  50   is the concentration that reduces 
bTREK-1 by 50%. Values are mean   ±   SEM of indicated number of determinations, (solid line) PKA activity = 1/[1+(X/EC  50  ) 
B  ], where 
X is the NPS-ACTH concentration, and B is the Hill coeffi  cient. EC  50   is the concentration that produces 1/2 of the maximum response. 
(D) Effect of PKA inhibitors on NPS-ACTH inhibition of bTREK-1. bTREK-1 current amplitudes are plotted against time. Pipette solu-
tion contained PKI(6  –  22)amide (4   μ  M) and H-89 (10   μ  M).         Liu et al.  285
  The ineffectiveness of 8-pCPT-2  ’  -O-Me-cAMP in per-
forated patch recordings suggested that ACTH and cAMP 
do not inhibit bTREK-1 through activation of Epac2. 
However, the membrane-permeable cAMP analogue 
8-pCPT-cAMP, which potently activates PKA and Epac2 
(Christensen et al., 2003), also failed to inhibit bTREK-1 
when applied at a concentration of 30   μ  M in perforated 
patch recordings (  Fig. 5, B and C  ). In contrast, at 10-fold 
higher concentrations, 8-pCPT-cAMP inhibited bTREK-1 
by 91.2   ±   6.7 (  n   = 3) (  Fig. 5, B and C  ). These fi  ndings in-
dicate that even in perforated patch recordings, cyclic 
nucleotides applied externally fail to reach intracellular 
concentrations that are comparable to those present in 
the bath solution. 
  Inhibition of bTREK-1 by Intracellular Application of 
8-pCPT-2  ’  -O-Me-cAMP 
  Because of the limited effectiveness of the cAMP ana-
logues when applied extracellularly at low concentra-
tions and the associated uncertainty of their intracellular 
concentrations, we measured the effects of 8-pCPT-2  ’  -O-
Me-cAMP on bTREK-1 K 
+   channel activity when it was 
8-pCPT-2  ’  -O-Me-cAMP has been reported to activate 
Epac1, but not PKA (Enserink et al., 2002). However, in 
experiments on bovine AZF cells, we found that at con-
centrations   >  30   μ  M, 8-pCPT-2  ’  -O-Me-cAMP produced 
signifi  cant increases in PKA activity. When applied ex-
ternally at 100   μ  M, this cAMP analogue increased PKA 
activity approximately threefold over the control value 
(unpublished data). 
  These PKA activity measurements demonstrated that 
8-pCPT-2  ’  -O-Me-cAMP could be used in bovine AZF cells 
as a selective Epac activator at concentrations up to 30   μ  M. 
To determine whether 8-pCPT-2  ’  -O-Me-cAMP could in-
hibit bTREK-1 independently of PKA, AZF cells were 
  superfused with this agent while recording bTREK-1 cur-
rents with the nystatin perforated patch technique ( Horn 
and Marty, 1988  ). By using this technique, we hoped to 
minimize cell dialysis allowing 8-pCPT-2  ’  -O-Me-cAMP to 
reach a higher intracellular concentration. However, in 
these experiments, 8-pCPT-2  ’  -O-Me-cAMP (30   μ  M) in-
hibited bTREK-1 by only 10.2  ±   6.4% ( n   = 5), while ACTH 
(200 pM) inhibited bTREK-1 under the same conditions 
by 83.8   ±   2.8% (  n   = 7) (  Fig. 5, A and C  ).   
  Figure 4.     Effect of PKA inhibitors on bTREK-1 
inhibition by forskolin. Whole cell K 
+   currents 
were recorded from AZF cells in response to volt-
age steps applied from     80 mV at 30-s intervals 
with or without 10-s depolarizing prepulses to 
    20 mV. Patch pipettes contained standard so-
lution or the same solution supplemented with 
PKI(6  –  22) amide (4   μ  M) alone or in combi-
nation with H-89 (5 or 10   μ  M). After bTREK-1 
current reached a stable maximum, cells were 
superfused with forskolin (2.5   μ  M). (A and B) K 
+   
current traces recorded with (right traces) and 
without (left traces) prepulses, and correspond-
ing plot of bTREK-1 amplitudes with (open cir-
cles) or without (closed circles) depolarizing 
pulses. Numbers on traces correspond to those 
on plots. (C) Summary of experiments as in 
A and B. Bars indicate mean   ±   SEM of bTREK-1 
inhibition by forskolin (2.5   μ  M) with or without 
PKA inhibitors, as indicated.     286   ACTH Inhibits bTREK-1 through Multiple cAMP-dependent Pathways  
Me-cAMP activated PKA in AZF cell lystates only at con-
centrations signifi  cantly higher than those required to 
inhibit bTREK-1 current (  Fig. 7 C  ).   
  Inhibition of bTREK-1 by 8-pCPT-2  ’  -O-Me-cAMP Is 
Independent of PKA 
  The suppression of bTREK-1 expression in AZF cells 
by 8-pCPT-2  ’  -O-Me-cAMP at concentrations that induce 
little or no activation of PKA indicate that this enzyme 
does not mediate the inhibition. Accordingly, 8-pCPT-
2  ’  -O-Me-cAMP was effective in inhibiting bTREK-1 activ-
ity in the presence of PKA antagonists. 
  In the experiments illustrated in   Fig. 7 (A and B)  , AZF 
cells were preincubated for at least 30 min with the cell-
permeable PKA inhibitor myristolyated PKI(14  –  22) amide 
(4   μ  M) and H-89 (5 or 10   μ  M) before recording K 
+   cur-
rents with pipettes containing PKI(6  –  22) amide (4   μ  M) 
and H-89 (5 or 10   μ  M) with no further addition or with 
8-pCPT-2  ’  -O-Me-cAMP at several concentrations. The PKA 
inhibitors failed to suppress bTREK-1 inhibition by 8-pCPT-
2  ’  -O-Me-cAMP at concentrations from 5 to 30   μ  M 
(  Fig. 7, A and B  ). In contrast, when PKI(6  –  22) amide 
and H-89 were added to AZF cell cytoplasmic extracts, 
applied directly to the cytoplasm through the pipette. 
When applied through the pipette at concentrations from 
1 to 30   μ  M, 8-pCPT-2  ’  -O-Me-cAMP potently and effec-
tively suppressed the time-dependent growth of bTREK-1 
with an IC  50   of 0.63   μ  M (  Fig. 6, A  –  D  ).   Notably, at a con-
centration of 1   μ  M, 8-pCPT-2  ’  -O-Me-cAMP reduced 
bTREK-1 current density by 63.7% from a control value 
of 45.2   ±   5.9 pA/pF (  n   = 15) to 16.4   ±   4.4 pA/pF (  n   = 6). 
Using this low concentration of 8-pCPT-2  ’  -O-Me-cAMP 
in the pipette, bTREK-1 amplitude initially grew, but then 
declined to a steady-state value (  Fig. 6 B  ). At higher con-
centrations, the initial increase in bTREK-1 amplitude 
was absent and inhibition of bTREK-1 activity was nearly 
complete (  Fig. 6, C and D  ). The inhibition of bTREK-1 
expression by 8-pCPT-2  ’  -O-Me-cAMP was specifi  c. This 
agent did not alter the expression of the voltage-gated 
Kv1.4 current in these cells (  Fig. 6 E  ). 
  When applied intracellularly through the patch pipette, 
8-pCPT-2  ’  -O-Me-cAMP inhibited bTREK-1 at concentra-
tions similar to those that activate Epac in vitro (EC  50   = 
2.2  μ  M). By comparison, 10 –  20-fold higher concentrations 
were required to activate PKA holoenzyme (Enserink 
et al., 2002). Accordingly, we found that 8-pCPT-2  ’  -O-
  Figure 5.     Effect of 8-pCPT-cAMP on bTREK-
1 currents in perforated patch recordings. 
(A and B) Perforated patch recordings: whole 
cell K 
+   currents were recorded in the nystatin 
perforated patch confi  guration in response 
to voltage steps applied at 30-s intervals from 
a holding potential of     80 to +20 mV with 
(right traces) or without (left traces) depo-
larizing prepulses. After bTREK-1 reached a 
stable amplitude, cells were superfused with 
8-pCPT-2  ’  -O-Me-cAMP (designated EA for 
Epac activator) (30   μ  M), ACTH (200 pM), or 
8-pCPT-cAMP (30 or 300   μ  M), as indicated. 
Numbers on current traces correspond to 
those on plot at right. (C) Summary of ex-
periments as in A and B. Bars indicate mean   ±   
SEM of indicated number of determinations.         Liu et al.  287
proceeds through an ATP hydrolysis-dependent mecha-
nism, then substitution of the nonhydrolyzable ATP 
analogue AMP-PNP for ATP in the pipette solution 
should eliminate inhibition by the Epac2 activator. Ac-
cordingly, when pipette solutions contained 2 mM AMP-
PNP in place of ATP, 8-pCPT-2  ’  -O-Me-cAMP (30   μ  M) 
failed to suppress bTREK-1 expression in whole cell re-
cordings (  Fig. 7 D  ). 
  Inhibition of bTREK-1 in Twice Patched Cells by 8-pCPT-2  ’  -
O-Me-cAMP 
  In whole cell recordings, intracellularly applied 8-pCPT-
2  ’  -O-Me-cAMP suppressed bTREK-1 expression, even 
when the AZF cell had been preincubated with PKA in-
hibitors, and the patch electrode contained PKA inhibi-
tors. To further demonstrate that 8-pCPT-2 ’  -O-Me-cAMP 
inhibited bTREK-1 under conditions where PKA activity 
had been totally blocked in advance, AZF cells were 
sequentially patched with a pipette containing the PKA 
PKA activation by 8-pCPT-2  ’  -O-Me-cAMP (1  –  30   μ  M) or 
cAMP (5   μ  M) was completely inhibited to levels below 
control values (  Fig. 7 C  ). Overall, 8-pCPT-2  ’  -O-Me-cAMP 
effectively suppressed bTREK-1 channel activity under 
conditions where PKA had been completely eliminated. 
  Adenosine-3    -5    -cyclic monophosphorothioate, Rp iso-
mer (Rp-cAMPS) competitively inhibits cAMP activation 
of PKA, but not Epac, in living cells (  Holz et al., 2008  ; 
  Poppe et al., 2008  ). The presence of 500   μ  M Rp-cAMPS 
in the pipette solution failed to blunt the complete in-
hibition of bTREK-1 by 8-pCPT-2  ’  -O-Me-cAMP (30   μ  M), 
providing further evidence for an Epac2-dependent in-
hibition of bTREK-1 (  Fig. 7, A and D  ). 
  Inhibition of bTREK-1 by 8-pCPT-2  ’  -O-Me-cAMP Requires 
Hydrolyzable ATP 
  The inhibition of bTREK-1 by ACTH and 8-pCPT-cAMP 
requires hydrolyzable ATP (  Enyeart et al., 1996  ). If 8-pCPT-
2  ’  -O-Me-cAMP  –  mediated inhibition of bTREK-1 also 
  Figure 6.     Concentration-dependent inhibition 
of bTREK-1 by 8-pCPT-2  ’  -O-Me-cAMP. K 
+   cur-
rents were recorded from AZF cells with stan-
dard pipette solution or the same solution 
supplemented with 8-pCPT-2 ’  -O-Me-cAMP (EA) 
at concentrations from 1 to 30   μ  M. Currents 
were recorded in response to voltage steps to 
+20 mV applied at 30-s intervals from a hold-
ing potential of     80 mV with and without 
depolarizing prepulses. (A  –  C) Time-dependent 
increase in bTREK-1 and inhibition by 8-pCPT-
2  ’  -O-Me-cAMP (EA). Current traces recorded 
with (right) and without (left) depolarizing 
prepulses at indicated times. bTREK-1 ampli-
tudes are plotted at right. Open circles indicate 
traces recorded with depolarizing prepulse. 
(D) Summary of experiments as in A  –  C. Bars 
indicate bTREK-1 current density in pA/pF 
expressed as the mean   ±   SEM of the indicated 
number of determinations. (E) Effect of 
8-pCPT-2  ’  -O-Me-cAMP (EA) on Kv1.4 current. 
Bars indicate Kv1.4 current density in pA/pF 
expressed as the mean   ±   SEM of the indicated 
number of determinations in control saline 
and in the presence of 8-pCPT-2  ’  -O-Me-cAMP 
(30   μ  M) (EA).     288   ACTH Inhibits bTREK-1 through Multiple cAMP-dependent Pathways  
pression of bTREK-1 mRNA and K 
+   channels (  Enyeart 
et al., 2003  ). We now report that, under similar con-
ditions, ACTH markedly suppresses the expression of 
Epac2 mRNA. In the experiment illustrated in   Fig. 9 A  , 
AZF cells were treated with ACTH (2 nM) for 48 h before 
isolating mRNA.   Northern analysis showed that Epac2-
specifi  c mRNA was markedly reduced, compared with 
its time-matched control. 
  When AZF cells were exposed to ACTH (10 nM) for 
72 or 96 h before recording K 
+   currents, 8-pCPT-2  ’  -O-
Me-cAMP failed to inhibit bTREK-1 expression. In the 
experiments illustrated in   Fig. 9 B, K   
+   currents were re-
corded from ACTH-treated cells with pipettes contain-
ing either standard solution plus PKA inhibitors, or the 
same solution supplemented with 8-pCPT-2  ’  -O-Me-cAMP 
(5   μ  M). The maximum bTREK-1 current densities were 
nearly identical in the absence or presence of the Epac 
activator. In contrast, when K 
+   currents were recorded 
from ACTH-treated cells using pipettes containing 8-br-
cAMP, which activates PKA as well as Epac2, bTREK-1 
was nearly completely inhibited (  Fig. 9 B  ). 
  In other experiments, AZF cells were treated for 72  –
  96 h with ACTH (10 nM) before patch clamping them 
with pipettes containing PKA inhibitors followed by 
antagonists, followed by one containing these antago-
nists as well as 8-pCPT-2  ’  -O-Me-cAMP. 
  Control experiments showed that AZF cells could of-
ten be consecutively patched with two pipettes without 
compromising the recording of bTREK-1 currents. In 
the experiment illustrated in   Fig. 8 A  , the cell was con-
secutively patched by two pipettes containing standard 
pipette solution.   bTREK-1 current amplitude remained 
relatively constant upon voltage clamping the cell with 
the second pipette. In contrast, when the second pipette 
contained 8-pCPT-2  ’  -O-Me-cAMP (15   μ  M), bTREK-1 was 
rapidly inhibited (  Fig. 8 B  ). Similar results were obtained 
in each of four experiments. 
  Finally, when cells were fi  rst voltage clamped with pi-
pettes containing PKI (4   μ  M) and H-89 (10   μ  M) to pre-
inhibit PKA, subsequent voltage clamp of the cell with 
patch electrodes containing the PKA inhibitors as well 
as 8-pCPT-2  ’  -O-Me-cAMP produced near complete in-
hibition of bTREK-1 (  Fig. 8 C  ). 
  8-pCPT-2  ’  -O-Me-cAMP Fails to Inhibit bTREK-1 when 
Epac2 Expression Is Suppressed by ACTH 
  In a previous study, we demonstrated that prolonged 
treatment of AZF cells with ACTH enhances the ex-
  Figure 7.     bTREK-1 inhi-
bition by 8-pCPT-2  ’  -O-Me-
cAMP is independent of PKA. 
(A  –  C) Whole cell K 
+   currents 
were recorded in response to 
voltage steps applied at 30-s 
intervals from     80 to +20 mV 
with or without depolarizing 
prepulses. Pipettes contained 
standard solution or the same 
solution supplemented with 
8-pCPT-2  ’  -O-Me-cAMP (EA), 
either alone or in combina-
tion with PKA inhibitors H-89 
(10   μ  M), PKI(6  –  22) amide 
(4   μ  M), and Rp-cAMPS (500 
  μ  M), as indicated. When 
pipettes contained PKA in-
hibitors H-89 and PKI(6  –  22), 
cells were also pretreated for 
30 min with H-89 (10   μ  M) 
and myristolated PKI(14  –  22) 
peptide (4   μ  M) before initi-
ating recording. (A) Plots of 
bTREK-1 amplitude against 
time with pipettes containing 
indicated solutions. (B) Sum-
mary of experiments as in A. 
Bars indicate bTREK-1 current density in pA/pF expressed as the mean   ±   SEM of the indicated number of determinations. (C) Effect of 
8-pCPT-2  ’  -O-Me-cAMP (EA) and PKA inhibitors on PKA activity in AZF cell lysates: PKA activity was determined in cell lysates after incu-
bating AZF cells either without (untreated) or with PKA inhibitors for 30 min. PKA activity in lysates from untreated cells was measured 
after 5 min with no further addition (control) or after addition of cAMP (5   μ  M) or 8-pCPT-2  ’  -O-Me-cAMP (1  –  30   μ  M) (EA). PKA activity 
in lysates from PKA inhibitor  –  treated cells was measured after 5 min incubation with cAMP (5   μ  M) or 8-pCPT-2  ’  -O-Me-cAMP (1  –  30   μ  M) 
(EA) and the PKA inhibitors as indicated. PKA activity is expressed as % of that activatable by 5   μ  M cAMP in control lysates. (D) Effect of 
AMP-PNP on 8-pCPT-2  ’  -O-Me-cAMP inhibition of bTREK-1 current. bTREK-1 current was measured at 30-s intervals using patch pipettes 
containing AMP-PNP (2 mM) in place of ATP, or this same solution plus 8-pCPT-2  ’  -O-Me-cAMP (30   μ  M) (EA). Bars represent mean   ±   
SEM of maximum current density for the indicated number of determinations.         Liu et al.  289
of mRNA from bovine AZF cells, Epac2 was readily de-
tected. By comparison, little or no Epac2 mRNA could 
be detected in HEK293 cells (  Fig. 10 D  ).   Experiments 
were done to determine whether 8-pCPT-2  ’  -O-Me-cAMP 
could inhibit the activity of cloned bTREK-1 channels 
expressed in HEK293 cells where Epac2 is poorly ex-
pressed. In contrast to its effect in bovine AZF cells, 
the presence of 8-pCPT-2  ’  -O-Me-cAMP in the pipette 
  solution at 5 or 15   μ  M failed to alter the functional 
  expression of bTREK-1 in transfected HEK293 cells 
(  Fig. 10, A and C  ). 
  Although Epac2 may be absent from HEK293 cells, 
these cells do express functional PKA ( Rich et al., 2007 ). 
N6-benzoyl-cAMP (6-Bnz-cAMP) is a cAMP analogue that 
selectively activates PKA over Epac (Christensen et al., 
2003). When 6-Bnz-cAMP (15   μ  M) was included in the 
pipette solution, the activity of transfected bTREK-1 K 
+   
channels in HEK293 cells was markedly suppressed 
from a control value of 141.2   ±   25.8 pA/pF (  n   = 19) to 
34.5   ±   6.4 pA/pF (  n   = 9) (  Fig. 10, B and D  ). These results 
PKA inhibitors plus 8-pCPT-2  ’  -O-Me-cAMP (5   μ  M). 
Under these conditions, 8-pCPT-2  ’  -O-Me-cAMP (5   μ  M) 
failed to produce any inhibition of bTREK-1 current in 
each of four cells (  Fig. 9 C  ). In fact, maximum bTREK-1 
density was slightly increased from 26.1   ±   3.0 to 29.6   ±   
7.9 pA/pF in the presence of the Epac activator. In 
contrast, when the experiment was repeated with cells 
that had not been pretreated with ACTH, 8-pCPT-
2  ’  -O-Me-cAMP inhibited bTREK-1 by 88.1   ±   3.1% 
(  n   = 4) (  Fig. 9 D  ). 
  8-pCPT-2  ’  -O-Me-cAMP Does Not Inhibit bTREK-1 Activity 
in Transfected HEK293 Cells 
  Epac2 is robustly expressed in a limited number of tis-
sues, including the adrenal glands of rats and humans 
(  Kawasaki et al., 1998  ). However, the distribution of 
Epac2 expression within the adrenal has not been de-
termined. Specifi  cally, it hasn  ’  t been shown that Epac2 
is expressed in adrenal cortical cells, rather than neural 
crest  –  derived adrenal chromaffi  n cells. In Northern blots 
  Figure 8.     Inhibition of bTREK-1 by 8-pCPT-
2  ’  -O-Me-cAMP in twice-patched cells. Whole 
cell K 
+   currents were recorded in response to 
voltage steps to +20 mV applied at 30-s inter-
vals from     80 mV, with or without depolariz-
ing prepulses. Cells were sequentially patched 
with two pipettes containing standard solu-
tion, or the same solution supplemented with 
PKI(6  –  22) amide (4   μ  M), H-89 (10   μ  M), or 
8-pCPT-2  ’  -O-Me-cAMP (EA) as indicated. When 
bTREK-1 reached a stable maximum, the fi  rst 
pipette was withdrawn and the cell patched 
again with the second pipette. (A  –  C) Current 
traces and corresponding plots of bTREK-1 
amplitude against time for cells patch clamped 
with pipettes containing the additions indi-
cated. Closed circles represent pipette #1, 
closed triangles, pipette #2. Numbers on 
traces at left correspond to those on plot at 
right. Break in graph denotes time required 
to change patch pipettes.     290   ACTH Inhibits bTREK-1 through Multiple cAMP-dependent Pathways  
  PKA-independent Inhibition of bTREK-1 by ACTH 
and Forskolin 
  Experiments in which PKI(6  –  22) amide and H-89 failed 
to blunt bTREK-1 inhibition by ACTH or forskolin pro-
vide convincing evidence that inhibition of this channel 
by cAMP can occur through a PKA-independent mecha-
nism. PKI(6  –  22) amide was used at concentrations 
    1,000  –  2,000 times the reported IC  50   of 1.7 nM (  Glass 
et al., 1989  ). H-89, which competes with ATP for its 
binding site on PKA, was used at 100  –  200 times its re-
ported IC  50   of   <  50 nM (  Hidaka et al., 1991  ). When ap-
plied together to AZF cell cytoplasmic extracts, these 
agents eliminated the activation of PKA by 8-pCPT-2  ’  -O-
Me-cAMP or cAMP. When applied together to the cyto-
plasm through the pipette solution, these agents should 
have completely blocked PKA activation by ACTH and 
forskolin, yet bTREK-1 inhibition was not affected. 
  The voltage-independent inhibition of bTREK-1 by 
ACTH and 8-pCPT-cAMP in the presence of PKA antag-
onists provided additional evidence that this response 
show that 8-pCPT-2  ’  -O-Me-cAMP fails to inhibit bTREK-1 
activity in cells that poorly express Epac2, while these 
same channels are inhibited in response to specifi  c acti-
vation of PKA. 
  DISCUSSION  
  The major fi  ndings of this study are that ACTH, NPS-
ACTH, and cAMP inhibit bTREK-1 K 
+   channels in bo-
vine AZF cells by multiple cAMP-dependent signaling 
pathways that likely involve the activation of both PKA 
and Epac2. bTREK-1 is among the fi  rst K 
+   channels 
identifi  ed thus far that is inhibited by parallel cAMP-de-
pendent pathways. ATP-sensitive K 
+   channels of pancre-
atic      cells are also inhibited by cAMP through separate 
PKA- and Epac-dependent mechanisms (  Light et al., 
2002  ;   Kang et al., 2008  ). The convergent inhibition of 
bTREK-1 K 
+   channels by these two cAMP-dependent 
mechanisms provides for effi  cient fail-safe depolariza-
tion of AZF cells by ACTH. 
  Figure 9.     Effect of suppression of Epac2 
expression on bTREK-1 inhibition by 8-pCPT-
2  ’  -O-Me-cAMP and 8-br-cAMP. (A) Northern 
blot analysis of ACTH inhibition of Epac2 
mRNA expression. AZF cells were cultured 
either without (control) or with ACTH 
(2nM). mRNA was isolated after 48 h and ana-
lyzed as described in Materials and methods. 
(B) 8-pCPT-2  ’  -O-Me-cAMP and bTREK-1 ex-
pression in ACTH-treated cells. AZF cells were 
exposed to ACTH (10 nM) for 72  –  96 h before 
patch clamping with pipettes containing PKI 
amide (6  –  22) (4   μ  M) and H89 (10   μ  M) (con-
trol), this same solution supplemented with 
8-pCPT-2  ’  -O-Me-cAMP (5   μ  M) (EA), or a solu-
tion containing 8-br-cAMP (15   μ  M). bTREK-1 
current amplitudes are plotted against time. 
Bar graphs: summary of bTREK-1 maximum 
current densities. Values are mean   ±   SEM 
of indicated number of determinations. 
(C and D) Effect of ACTH treatment on 
bTREK-1 inhibition by 8-pCPT-2  ’  -O-Me-cAMP 
in twice-patched cells. AZF cells were cultured 
in serum-supplemented media with (C) or 
without (D) 10 nM ACTH for 72  –  96 h before 
sequentially recording K 
+   currents with pi-
pettes containing PKI amide (6  –  22) (4   μ  M) 
plus H89 (10   μ  M) and then these two agents 
plus 8-pCPT-2  ’  -O-Me-cAMP (EA) (5   μ  M). K 
+   
current traces recorded with (right traces) and 
without (left traces) depolarizing prepulses. 
Numbers on traces correspond to those on 
plots of bTREK-1 amplitude at right.         Liu et al.  291
mainly by Ca 
2+   released from intracellular sites, while 
ACTH-mediated increases in [Ca 
2+  ]  i   occur in response to 
Ca 
2+   infl  ux through voltage-gated Ca 
2+   channels (  Yamazaki 
et al., 1998  ;   Hunyady and Catt, 2005  ). In whole-cell patch 
clamp experiments where cells are voltage clamped at 
    80 mV, ACTH-stimulated infl  ux through voltage-gated 
channels would be eliminated, preempting a Ca 
2+  -depen-
dent inhibition of bTREK-1. Under physiological condi-
tions, Ca 
2+   entry through voltage-gated channels could 
contribute to ACTH-stimulated bTREK-1 inhibition and 
membrane depolarization. 
  NPS-ACTH did increase the concentration of cAMP in 
AZF cells to a level suffi  cient to activate PKA. However, 
similar to ACTH, the inhibition of bTREK-1 by NPS-
ACTH appeared not to be mediated by PKA. First, 
NPS-ACTH inhibited bTREK-1 half-maximally at a con-
centration 16-fold lower than that required for half-maxi-
mal activation of PKA. Second, TREK-1 inhibition by 
NPS-ACTH was insensitive to PKA inhibitors. Overall, 
these results are consistent with a mechanism where, 
was not mediated through PKA. Previous studies showed 
that inhibition of neuronal TREK-1 channels by PKA-
dependent phosphorylation occurred through a right-
ward shift in the voltage-dependent activation of these 
channels (  Bockenhauer et al., 2001  ;   Maingret et al., 
2002  ). Consequently, open probability was not reduced 
at positive test voltages. In AZF cells, bTREK-1 was effec-
tively inhibited by ACTH and 8-pCPT-cAMP regardless 
of test potential, suggesting the involvement of a sepa-
rate PKA-independent mechanism. 
  Ca 
2+  - and PKA-independent Inhibition of bTREK-1 
by NPS-ACTH 
  NPS-ACTH reversibly inhibited bTREK-1 current with 
an IC  50   of 20 pM. Although this peptide was reported to 
trigger step-like and repetitive spike-like increases in 
[Ca 
2+  ]  i   in bovine AZF cells (  Yamazaki et al., 1998  ), it 
failed to inhibit bTREK-1 through a Ca 
2+  -dependent 
pathway similar to that activated by AngII. In this re-
gard, AngII-stimulated increases in [Ca 
2+  ]  i   are mediated 
  Figure 10.     6-Bnz-cAMP but not 8-pCPT-
2  ’  -O-Me-cAMP inhibits bTREK-1 channels 
expressed in HEK293 cells. Whole cell K 
+   
currents were recorded from HEK293 cells 
that had been transiently transfected with 
pCR3.1 uni-bTREK-1 cDNA. K 
+   currents were 
activated by voltage steps to +20 mV, applied 
at 30-s intervals from a holding potential of 
    80 mV. Patch pipettes contained control sa-
line or this same solution supplemented with 
8-pCPT-2  ’  -O-Me-cAMP (5 or 15   μ  M) (EA) or 
6-Bnz-cAMP (15   μ  M). (A and B) Effect of 
8-pCPT-2  ’  -O-Me-cAMP (EA) and 6-Bnz-cAMP 
on bTREK-1 current. bTREK-1 current traces 
and associated time-dependent plots of cur-
rent amplitudes. Numbers on traces corre-
spond to those on plots at right. (C) Summary 
of experiments as shown in A and B. Bars 
  indicate maximum bTREK-1 current density 
expressed as pA/pF. Values are mean   ±   SEM 
for indicated number of determinations. 
(D) Northern blot analysis of Epac2 in bovine 
AZF and HEK293 cells. Lanes contained 7   μ  g 
of poly(A) 
+   RNA from the indicated cells. 
Hybridization with hEpac2 probe was performed 
as described in Materials and methods.     292   ACTH Inhibits bTREK-1 through Multiple cAMP-dependent Pathways  
the IC  50   20-fold (  Kang et al., 2008  ). bTREK-1 inhibition 
by this Epac-selective cyclic nucleotide occurs through a 
different mechanism, since inhibition is blocked when 
AMP-PNP replaces ATP in the pipette solution, indicat-
ing a requirement for ATP hydrolysis. Specifi  c protein 
kinases activated by Epac2 have not been identifi  ed. 
  The failure of membrane-permeable 8  ’  -substituted 
cAMP derivatives, including 8-pCPT-cAMP and 8-pCPT-2  ’  -
O-Me-cAMP to inhibit bTREK-1 when superfused exter-
nally at low concentrations in perforated patch recordings 
was unexpected. In perforated patch recording, whole cell 
dialysis is presumably limited when compared with stan-
dard whole cell recording. In standard whole cell record-
ing, we previously found that 8-pCPT-cAMP inhibited 
bTREK-1 channels with an IC  50   of 167   μ  M, a concentra-
tion much higher than that required to activate PKA in 
intact AZF cells (  Enyeart et al., 1996  ). Similar high con-
centrations of 8-pCPT-cAMP were also required to inhibit 
bTREK-1 in perforated patch recordings. 
  It seems likely that the reduced potency of cyclic nu-
cleotides applied externally in perforated patch recordings 
stems from limited transport across the cell membrane. 
Their potency as bTREK-1 inhibitors increased mark-
edly when they were directly applied to the cytoplasm 
through the patch pipette. Similar results have been seen 
in a study of the inhibition of K  ATP   K 
+   channels by Epac-
selective cAMP analogues in pancreatic      cells (  Kang 
et al., 2006  ). 
  Overall, the selectivity of 8-pCPT-2  ’  -O-Me-cAMP as an 
Epac-specifi  c activator may have been overstated in the 
initial studies of this and similar compounds (Enserink 
et al., 2002; Christensen et al., 2003;   Rehmann et al., 
2003  ). It is clear that when applied externally to intact 
cells at concentrations   >  50   μ  M, these agents produce 
signifi  cant activation of PKA and possibly other cAMP-
activated proteins. Results obtained from experiments 
where these agents were used at concentrations of 100   μ  M 
or more in the absence of PKA inhibitors should be in-
terpreted with caution. 
  Although we have found that bovine AZF cells express 
Epac2 and that an Epac-selective cAMP analogue inhib-
its bTREK-1 at low concentrations under conditions 
where PKA is inhibited, and fails to inhibit bTREK-1 in 
cells when Epac2 expression has been suppressed, the 
possibility remains that 8-pCPT-2  ’  -O-Me-cAMP inhibits 
bTREK-1 through a cAMP-binding protein different than 
PKA or Epac2. PKA- and Epac-independent actions of 
cAMP have been observed in neurons and endocrine 
cells (  Ivins et al., 2004  ;   Gambaryan et al., 2006  ). 
  Our results demonstrate that ACTH inhibits bTREK-1 
K 
+   channels in bovine AZF cells through activation of 
multiple cAMP-dependent signaling pathways. The con-
vergent inhibition of bTREK-1 through separate PKA- 
and Epac2-dependent signaling pathways provides an 
effi  cient, reliable mechanism for membrane depolariza-
tion and Ca 
2+   entry. 
similar to ACTH, NPS-ACTH can inhibit bTREK-1 by a 
PKA-independent action of cAMP. 
  Inhibition of bTREK-1 by 8-pCPT-2  ’  -O-Me-cAMP 
  8-pCPT-2  ’  -O-Me-cAMP potently and effectively inhib-
ited bTREK-1 activity when applied intracellularly 
through the patch pipette in whole cell recordings. Sev-
eral lines of evidence strongly indicate that this inhibition 
was mediated through Epac2. First, bTREK-1 expression 
was inhibited half-maximally with an IC  50   of   <  1   μ  M. This 
result is in excellent agreement with that reported for 
the potency of this agent in activating Epac1 and Epac2, 
where binding affi  nities and EC  50  s of 1  –  5   μ  M have been 
reported (Enserink et al., 2002;   Bos, 2003  ;   Rehmann 
et al., 2003  ). In contrast, 8-pCPT-2  ’  -O-Me-cAMP acti-
vates PKA only at 10  –  20-fold higher concentrations, and 
is far less effective than cAMP in this respect (Enserink 
et al., 2002;   Bos, 2003  ). 
  Further, we showed that 8-pCPT-2  ’  -O-Me-cAMP inhib-
ited bTREK-1 completely at concentrations that pro-
duced little or no measurable increase in PKA activity in 
AZF cells. This agent also effectively inhibited bTREK-1 
activity in cells where PKA had been inhibited by prein-
cubating cells with PKA inhibitors and with these inhib-
itors included in the patch pipette at concentrations 
100  –  1,000 times their reported EC  50  s. Third, 8-pCPT-2  ’  -
O-Me-cAMP inhibited bTREK-1 in twice-patched cells 
where PKA was fi  rst preinhibited by direct application 
of the two PKA inhibitors to the cytoplasm through 
the patch pipette. Finally, 8-pCPT-2  ’  -O-Me-cAMP was in-
effective at inhibiting bTREK-1 channels when Epac2 
expression had been suppressed by prolonged expo-
sure of AZF cells to ACTH, or in HEK293 cells that ex-
press little or no Epac2. In contrast, cAMP derivatives 
that activate PKA retained their effectiveness in these 
two systems. 
  It isn  ’  t known whether cAMP might also inhibit 
bTREK-1 in other cells through PKA- and Epac2-depen-
dent signaling pathways. Since the expression of Epac2 is 
limited, other cells expressing both Epac2 and bTREK-1 
have not yet been identifi  ed. It is possible that TREK-1 
inhibition through Epac2 could occur in selected CNS 
neurons that express both of these proteins. 
  Signaling Mechanism for bTREK-1 Inhibition by 8-pCPT-2  ’  -
O-Me-cAMP 
  The mechanism by which 8-pCPT-2  ’  -O-Me-cAMP inhib-
its bTREK-1 K 
+   channels after activation of Epac2 is un-
known. This Epac-selective cAMP analogue inhibits K  ATP   
K 
+   channels of pancreatic      cells and cell lines through 
an Epac2-dependent mechanism, wherein activated Epac2 
interacts with the sulfonylurea receptor 1, a subunit of 
this inwardly rectifying K 
+   channel to reduce channel 
activity (  Kang et al., 2006  ). Further, it has recently been 
shown that Epac-selective cAMP activators function by 
sensitizing K  ATP   K 
+   channels to inhibition by ATP, shifting     Liu et al.  293
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